Neurológia pre prax 1/2023
The use of anti-CGRP monoclonal antibodies amongst wide variety of patients
Monoclonal CGRP antibodies represent a specific type of migraine profylaction. A high effectivity on both episodic and chronic migraine including concomitant medication overuse headache was proven in scientific studies as well as in clinical practice. Once-monthly or once-quarterly dosing improving the therapy adherence proved to be the main advantage of the treatment. The therapy is well tolerated by patients. Monoclonal CGRP antibodies do not affect the immune system and do not have drug interactions.
Keywords: monoclonal antibodies, CGRP, migraine, erenumab, fremanezumab, galcanezumab, eptinezumab
